<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806338</url>
  </required_header>
  <id_info>
    <org_study_id>MSI-1436C-102</org_study_id>
    <nct_id>NCT00806338</nct_id>
  </id_info>
  <brief_title>An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers</brief_title>
  <official_title>A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Multiple Dose Tolerance and Pharmacokinetic Study of Trodusquemine (MSI-1436) in Obese or Overweight Type 2 Diabetic Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genaera Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genaera Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerance of multiple intravenous&#xD;
      (through a vein) doses of trodusquemine (MSI-1436) in obese or overweight, type 2 diabetics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Different amounts of trodusquemine (MSI-1436) will be given to each volunteer group&#xD;
      throughout the study. Another purpose is to evaluate the pharmacokinetics (PK - the study of&#xD;
      the way the drug enters and leaves the blood and tissues over time) of trodusquemine&#xD;
      (MSI-1436). Finally, this study will also determine whether trodusquemine (MSI-1436) has any&#xD;
      effect on appetite, mood or behavior, and selective biomarkers (substances in your blood that&#xD;
      may change in response to the study drug).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerance of multiple intravenous doses of trodusquemine (MSI-1436) in obese or overweight type 2 diabetics. Safety will be evaluated by physical exams, vital signs assessments, 12-lead ECGs, clinical lab tests and adverse event profile.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on glucose tolerance or glucose/insulin relationships</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on appetite and food consumption</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on behavior and mood</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on exploratory biomarkers</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Trodusquemine (MSI-1436) 3mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Trodusquemine (MSI-1436) 6mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Trodusquemine (MSI-1436) 10mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trodusquemine (MSI-1436)</intervention_name>
    <description>A single dose of Trodusquemine (MSI-1436) will be administered every 72 hours on Days 0, 3, 6, 9, 12, 15, 18 and 21. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2 and 10mg/m2 in cohort 3.</description>
    <arm_group_label>Trodusquemine (MSI-1436) 10mg/m2</arm_group_label>
    <arm_group_label>Trodusquemine (MSI-1436) 3mg/m2</arm_group_label>
    <arm_group_label>Trodusquemine (MSI-1436) 6mg/m2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. male or female obese or overweight type 2 diabetic subjects, between 18 and 65 years&#xD;
             old (inclusive) either treatment naïve or who are inadequately controlled on metformin&#xD;
             alone;&#xD;
&#xD;
          2. subjects receiving metformin should be on stable dose for at least two weeks prior to&#xD;
             enrollment;&#xD;
&#xD;
          3. have a fasting blood sugar of ≥ 100 mg/dL and hemoglobin A1C ≥ 7.5% (but ≤ 11.0%) at&#xD;
             study entry;&#xD;
&#xD;
          4. of any race who are in good health (based on medical history, physical examination,&#xD;
             electrocardiograms [ECGs], and clinical laboratory tests);&#xD;
&#xD;
          5. non-smokers (refrained from any tobacco or nicotine usage, including smokeless&#xD;
             tobacco, nicotine patches, etc.,) for 6 months prior to Day 0 of the study. Subjects&#xD;
             must have cotinine levels below those measured for smokers based on reference lab&#xD;
             values;&#xD;
&#xD;
          6. body mass index (BMI) of 27-40 kg/m2;&#xD;
&#xD;
          7. able to execute informed written consent;&#xD;
&#xD;
          8. willingness to remain in the clinic for the inpatient portion of the study and return&#xD;
             for follow-up visits as required by the protocol and as deemed necessary by the&#xD;
             Principal Investigator;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. likely allergy or sensitivity to any components of Trodusquemine (MSI-1436C) for&#xD;
             Injection;&#xD;
&#xD;
          2. any subject with a history of severe allergy or bronchial asthma;&#xD;
&#xD;
          3. a clinically significant history of or current abnormality or disease of any organ&#xD;
             system, including renal, hepatic, gastrointestinal, cardiovascular (except&#xD;
             hyperlipidemia or controlled hypertension), pulmonary (including chronic asthma),&#xD;
             endocrine (except diabetes), central nervous, or hematologic systems, or recent&#xD;
             clinically significant surgery;&#xD;
&#xD;
          4. history of seizure, epilepsy, severe head injury, multiple sclerosis, or other known&#xD;
             neurological conditions;&#xD;
&#xD;
          5. abnormal pre-admission vital signs, physical examination, clinical laboratory, or any&#xD;
             safety variable which is considered clinically significant for this population by the&#xD;
             Principal Investigator or Sponsor (or designee). Subjects with an abnormal serum&#xD;
             creatinine should not be enrolled. Subjects with AST (SGOT), ALT (SGPT), GGT, alkaline&#xD;
             phosphatase, bilirubin, blood urea nitrogen (BUN), prothrombin time (PT), or activated&#xD;
             partial thromboplastin time (aPPT) &gt;1.5 times above the upper limit of normal should&#xD;
             not be enrolled;&#xD;
&#xD;
          6. any subject with a clinically significant mental or physical illness within 1 year&#xD;
             prior to the first dose, including a history of alcohol and/or drug abuse within 1&#xD;
             year prior to the first dose of study medication;&#xD;
&#xD;
          7. Insulin requiring diabetics;&#xD;
&#xD;
          8. any subject who has received any known hepatic or renal clearance altering agents (eg,&#xD;
             erythromycin, cimetidine, barbiturates, phenothiazines, St. John's Wort, etc.) within&#xD;
             a period of 90 days prior to the first dose of study medication;&#xD;
&#xD;
          9. any subject who has received any approved prescription anti-obesity drug or has taken&#xD;
             any over-the-counter medication for weight loss or who has received a&#xD;
             thiazolidinedione or exanatide within a period of 90 days prior to the first dose of&#xD;
             study medication;&#xD;
&#xD;
         10. ingestion or use of any investigational medication or device within 60 days prior to&#xD;
             the first dose of study medication; ingestion or use of any investigational&#xD;
             anti-obesity medication is prohibited within 3 months prior to the first dose of study&#xD;
             medication;&#xD;
&#xD;
         11. any subject with history of malignancy in last 5 years, with exception of basal and&#xD;
             squamous cell carcinomas of the skin;&#xD;
&#xD;
         12. any subject who is positive for HBsAG, Hepatitis C antibody, Hepatitis A IgM, or Human&#xD;
             Immunodeficiency Virus (HIV) Viral Serology tests at the screening visit;&#xD;
&#xD;
         13. a positive qualitative urine drug or alcohol test at screening or at check-in;&#xD;
&#xD;
         14. mental capacity is limited to the extent that the subject cannot provide legal consent&#xD;
             or understand information regarding the study;&#xD;
&#xD;
         15. any subject who has had a 10% weight loss in the past 3 months prior to the screening&#xD;
             visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Kipnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>dgd Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilbert Weiner, D.O. AOBFP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>dgd Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>January 21, 2008</study_first_submitted>
  <study_first_submitted_qc>December 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2008</study_first_posted>
  <last_update_submitted>April 14, 2009</last_update_submitted>
  <last_update_submitted_qc>April 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Michael Gast, MD, PhD</name_title>
    <organization>Genaera Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

